“Real-World” Outcomes of Transcatheter Mitral Valve Repair for Degenerative Mitral Regurgitation

In a national registry study, successful repair was associated with lower mortality and heart failure hospitalization rates.

Transcatheter mitral valve edge-to-edge repair (TEER) for degenerative mitral regurgitation (DMR) is FDA approved for patients deemed high risk for surgery. In practice, the population receiving this therapy is broader than the highly selected clinical trial populations upon which approval was based. The current study reports outcomes in all 19,088 patients who underwent TEER with MitraClip in the U.S. between 2014 and 2022.

The patients' median age was 82 years, and 48% were women. The median predicted risk for 30-day mortality was 4.6%, and surgical risk was categorized as high (22%), intermediate (68%), and low (10%). Site-reported success (MR moderate or less and gradient <10 mm Hg) was about 90%. Among patients with successful repair, m…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)